Redcare Pharmacy stock at EUR 74.33, up 0.45% premarket
Published on 11/04/2026 at 08:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRx growth sets the tone
- Redcare Pharmacy reported stronger German prescription sales and a second consecutive profitable quarter.
- Management retained its upgraded 2026 targets after the third-quarter update.
- The company enters the session with prescription medicines as its main growth driver.
Rx growth sets the tone
Redcare Pharmacy stock traded at EUR 74.33 on Lang & Schwarz at 08:14 CET on Wednesday, November 4, 2026, 0.45 percent above the Xetra close of Tuesday, November 3, 2026 at EUR 74.00. The real-time quote of Redcare Pharmacy stock points to a firmer start before the Xetra session.
The online pharmacy is coming off a strong third quarter. German prescription sales remained the key growth engine, while the company posted a second consecutive profitable quarter. Management kept its upgraded targets for 2026, leaving revenue growth and adjusted EBITDA margin ambitions unchanged after the latest update.
For investors, the main issue is whether prescription growth can continue to offset more moderate momentum in non-prescription products. The company is also moving into the important final quarter, when seasonal demand and marketing intensity can influence margins and cash generation.
European shares provide the broader regional backdrop, with the Euro Stoxx 50 serving as a key benchmark for market sentiment.
More news and analyses on Redcare Pharmacy stock will track prescription trends, profitability and the company's 2026 targets.
